SciELO - Scientific Electronic Library Online

 
vol.58 issue3Association between non-alcoholic fatty liver disease and liver function/injury markers with metabolic syndrome components in class III obese individualsAsthma and ambient pollutants: a time series study author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Revista da Associação Médica Brasileira

Print version ISSN 0104-4230

Abstract

NITA, Marcelo Eidi et al. Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the brazilian private health system. Rev. Assoc. Med. Bras. [online]. 2012, vol.58, n.3, pp. 294-301. ISSN 0104-4230.  http://dx.doi.org/10.1590/S0104-42302012000300008.

OBJECTIVES: To compare costs and clinical benefits of three additional therapies to metformin (MF) for patients with diabetes mellitus type 2 (DM2). METHODS: A discrete event simulation model was built to estimate the cost-utility ratio (cost per quality-adjusted life years [QALY]) of saxagliptine as an additional therapy to MF when compared to rosiglitazone or pioglitazone. A budget impact model (BIM) was built to simulate the economic impact of saxagliptine use in the context of the Brazilian private health system. RESULTS: The acquiring medication costs for the hypothetical patient group analyzed in a time frame of three years, were R$ 10,850,185, R$ 14,836,265 and R$ 14,679,099 for saxagliptine, pioglitazone and rosiglitazone, respectively. Saxagliptine showed lower costs and greater effectiveness in both comparisons, with projected savings for the first three years of R$ 3,874 and R$ 3,996, respectively. The BIM estimated cumulative savings of R$ 417,958 with the repayment of saxagliptine in three years from the perspective of a health plan with 1,000,000 covered individuals. CONCLUSION: From the perspective of private paying source, the projection is that adding saxagliptine with MF save costs when compared with the addition of rosiglitazone or pioglitazone in patients with DM2 that have not reached the HbA1c goal with metformin monotherapy. The BIM of including saxagliptine in the reimbursement lists of health plans indicated significant savings on the three-year horizon.

Keywords : health economics; diabetes mellitus type 2; health management; therapeutics; pharmacy and therapeutics committee; cost-effectiveness assessment.

        · abstract in Portuguese     · text in English | Portuguese     · pdf in English | Portuguese